References
- Anderson PH, Lam NN, Turner AG, et al. (2013). The pleiotropic effects of vitamin D in bone. J Steroid Biochem Mol Biol 136:190–4
- Bardou M, Barkun AN, Hamza S, et al. (2012). Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert Opin Drug Metab Toxicol 8:1199–208
- de Vries F, Cooper AL, Cockle SM, et al. (2009). Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989–98
- Eom CS, Park SM, Myung SK, et al. (2011). Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med 9:257–67
- Federico A, Nardone G, Gravina AG, et al. (2012). Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 143:55–61 e1; quize e13–14
- Jung HK. (2010). Is there any association of osteoporosis with proton pump inhibitor use? J Neurogastroenterol Motil 16:335–6.
- Lerchbaum E, Obermayer-Pietsch B. (2012). Vitamin D and fertility: A systematic review. Eur J Endocrinol 166:765–78
- Madanick RD. (2011). Proton pump inhibitor side effects and drug interactions: Much ado about nothing. Cleve Clin J Med 78:39–49
- Sanchez-Delgado J, Garcia-Iglesias P, Castro-Fernandez M, et al. (2012). High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 36:190–6
- Talley NJ, Jung HK, Jiang X, Locke GR. (2007). Is there an increased risk of hip fracture in patients on long-term PPI therapy. Nat Clin Pract Gastroenterol Hepatol 4:420–1
- Targownik LE, Lix LM, Leung S, Leslie WD. (2010). Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904
- Vakil N. (2012). Prescribing proton pump inhibitors: Is it time to pause and rethink. Drugs 72:437–45
- Vestergaard P. (2012). Systematic review of observational studies finds increased risk of fracture among older adults taking a proton pump inhibitor. Evid Based Med 17:39–40
- Vestergaard P, Rejnmark L, Mosekilde L. (2006). Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83
- Yang YX, Lewis JD, Epstein S, Metz DC. (2006). Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–53
- Yu EW, Blackwell T, Ensrud KE, et al. (2008). Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–9